The long-term fate of mesenchymal stem cells labeled with magnetic resonance imaging-visible polymersomes in …Dove Medical PressAbstract: Understanding the long-term fate and potential mechanisms of mesenchymal stem cells (MSCs) after transplantation… Continue reading
Scientists create new motor neurons out of skin cellsFuturity: Research NewsScientists have converted human skin cells from adults directly into motor neurons without going through a stem cell state. Motor neurons drive muscle contractions, and their d… Continue reading
BloombergDoes Immunotherapy Offer Hope to Finally End Cancer?BloombergCancer kills 8 million people per year. Immunotherapy is a promising breakthrough treatment. Bloomberg QuickTake delves into the cutting-edge medical science behind immunotherapy for… Continue reading
BloombergDoes Immunotherapy Offer Hope to Finally End Cancer?BloombergCancer kills 8 million people per year. Immunotherapy is a promising breakthrough treatment. Bloomberg QuickTake delves into the cutting-edge medical science behind immunotherapy for… Continue reading
|
Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after …
Newswise (press release) Newswise — The immunotherapy drug nivolumab is safer and more effective than ipilimumab—the current standard of care—in treating patients with resected stage III and stage IV melanoma, according to an international clinical trial led by a researcher … |
Targeted Oncology |
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
Targeted Oncology Tumor mutation burden in blood (bTMB) ≥16 had a significant association with improved progression-free survival (PFS) in patients treated with the PD-L1 inhibitor atezolizumab (Tecentriq), according to findings reported at the 2017 ESMO Congress. |
|
Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after …
Markets Insider NEW YORK, Sept. 10, 2017 /PRNewswire-USNewswire/ — The immunotherapy drug nivolumab is safer and more effective than ipilimumab—the current standard of care—in treating patients with resected stage III and stage IV melanoma, according to an … |
PR Newswire (press release) |
Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after …
PR Newswire (press release) NEW YORK, Sept. 10, 2017 /PRNewswire-USNewswire/ — The immunotherapy drug nivolumab is safer and more effective than ipilimumab—the current standard of care—in treating patients with resected stage III and stage IV melanoma, according to an … |